首页> 外文期刊>Breast cancer research and treatment. >Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
【24h】

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.

机译:聚(ADP-核糖)聚合酶-1 mRNA在人乳腺癌中的表达:一项荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Although poly(ADP-ribose) polymerase-1 (PARP1) inhibition is a recent promising therapy in breast cancer, PARP1 expression in this disease is not known. Using DNA microarray and array-based comparative genomic hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number alterations in 326 invasive breast cancer samples and normal breast (NB) samples. A meta-analysis was performed on a large public retrospective gene expression data set (n = 2,485) to analyze correlation between PARP1 mRNA expression and molecular subtypes and clinico-pathological parameters. PARP1 was overexpressed in 58% of cancers, and its expression was heterogeneous between tumors. ArrayCGH data revealed an association between mRNA overexpression and gain/amplification at the PARP1 locus (P < 1.0E-8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers (P < 1.0E-72), but overexpression was also found in other subtypes. PARP1 expression correlated with high grade, medullary histological type, tumor size, and worse metastasis-free survival (MFS; HR = 1.12 [1.04-1.22], P = 0.004) and overall survival (OS; HR = 1.16 [1.04-1.29], P = 0.006). In multivariate analysis, PARP1 expression had an independent prognostic value for MFS, which was restricted to patients untreated with any adjuvant chemotherapy. These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes.
机译:尽管聚(ADP-核糖)聚合酶-1(PARP1)抑制是乳腺癌中最近有希望的治疗方法,但该疾病中PARP1的表达尚不清楚。使用DNA芯片和基于阵列的比较基因组杂交(arrayCGH),我们检查了326例浸润性乳腺癌样品和正常乳腺(NB)样品中PARP1 mRNA的表达和拷贝数变化。对大型公共回顾性基因表达数据集(n = 2,485)进行荟萃分析,以分析PARP1 mRNA表达与分子亚型和临床病理参数之间的相关性。 PARP1在58%的癌症中过表达,其表达在肿瘤之间异质。 ArrayCGH数据显示了mRNA过表达与PARP1基因座处的增益/扩增之间的相关性(P <1.0E-8)。荟萃分析显示,PARP1表达在基础乳腺癌中较高(P <1.0E-72),但在其他亚型中也发现过表达。 PARP1表达与高级别,髓样组织学类型,肿瘤大小和较差的无转移生存期(MFS; HR = 1.12 [1.04-1.22],P = 0.004)和总生存期(OS; HR = 1.16 [1.04-1.29])相关,P = 0.006)。在多变量分析中,PARP1表达对MFS具有独立的预后价值,仅限于未经任何辅助化疗治疗的患者。这些数据表明,PARP1在许多乳腺癌中均过表达,并支持基础亚型以及其他乳腺癌亚型中PARP抑制剂的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号